Navigation Links
FavId in Medical News

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

New Product Name Also Unveiled in Ongoing Preparation for Commercial Launch SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that new data, including f...
FavId in Medical Technology

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European Hematology Association SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced interim data from a Phase 2 clinical trial...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...domized, double-blind, placebo controlled trial of favid following Rituxan(R) treatment in patients with fo... patients were randomly assigned to receive either favid plus Leukine(R) (sargramostim, GM-CSF) or placebo ...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ing them potentially more active as well." About favid favid is a patient-specific, Id/KLH active immunotherapy...nrollment in its pivotal Phase 3 clinical trial of favid following Rituxan(R) induction therapy in patients...
FavId in Biological Technology

Favrille Announces $21.1 Million Registered Direct Offering

...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas... development, testing, manufacturing and marketing favid or Favrille's other product candidates; delays in ...can serve as the basis for accelerated approval of favid and whether it will receive expedited review as a ...

Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007

...eases of the immune system. The Company's lead product candidate, FavId(R), is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clin...

Favrille to Present at BIO InvestorForum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at Bear Stearns Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...
Other Tags
(Date:9/4/2015)... ... September 04, 2015 , ... With TransCel from Pixel ... all within Final Cut Pro X. With TransCel users have full control over camera ... background color, speed method, frame color, inner color, text, and more. With TransCel the ...
(Date:9/4/2015)... ... 2015 , ... The Schmidt National Law Group filed an Essure® lawsuit against ... National Law Group, a leading firm in mass-tort litigation, has filed a lawsuit in ... Inc., and other Bayer affiliates for injuries alleged to have been caused by her ...
(Date:9/4/2015)... ... 04, 2015 , ... IVF New England, one of the largest and most ... Hour" in Manchester for women who wish to learn more about their fertility and ... and lounge, 827 Elm Street, Manchester, NH from 6PM to 7PM , This hip, ...
(Date:9/4/2015)... Marietta, GA (PRWEB) , ... September 04, 2015 , ... ... team is in desperate need of new apparel. In an effort to assist the ... around Marietta, has launched a charity drive to raise funds for the new uniforms. ...
(Date:9/4/2015)... ... September 04, 2015 , ... A ... Compassion Project. Core Compassion Project is a non-profit organization dedicated to offering ... side effects of cancer treatments and recover their mobility, strength, and range of ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
Other Contents